① Haisheng Pharmaceutical's “most stubborn” plan to increase its holdings with 100 shares sparked a buzz in the market. The company issued an announcement at midnight, sincerely apologizing to investors. ② The company's previous commitment arrangements in the prospectus were not well considered, and sufficient space was not reserved for specific implementation, leading to formality in the stock price stabilization plan. ③ The company recently stated that it will promptly study and formulate a practical price stabilization plan and release it as soon as possible after implementing the relevant decision-making procedures.
Financial Services Association, March 6 (Reporter Wu Chao) Haisheng Pharmaceutical (870656.BJ) sparked a buzz in the market due to the “most humble” announcement to increase its holdings. Actual controllers Ye Shanhai and Ye Jinzhi's plan to increase their holdings by no more than 100 shares, and the stable stock price plan of no more than 1990 yuan made investors dumbfounded. Faced with public pressure and investors' questions, Haisheng Pharmaceutical issued an announcement at midnight to sincerely apologize to investors.
Haisheng Pharmaceutical said in an announcement that the company recently received an “Application to Adjust Price Stability Measures” from actual controllers Ye Shanhai and Ye Jinzhi. In order to protect investors' interests, stabilize the company's stock price, and increase the company's value, the actual controller applied to adjust the arrangement of measures to stabilize the stock price, including but not limited to measures such as extending the actual controller's share lock-up period and increasing investor returns.
According to information, since Haisheng Pharmaceutical landed on the Beijing Stock Exchange at the beginning of last month, its stock price has been sluggish, falling below the issuance price for more than 10 consecutive trading days, thus triggering the conditions for starting the measures to stabilize the stock price in the prospectus.
However, while the market was expecting the company to introduce strong measures, it waited for the “most stubborn” plan to increase its holdings.
A Financial Services News reporter checked Juchao Network today. Haisheng Pharmaceutical explained in the “Notice on Implementing a Stable Stock Price Plan” issued on March 1 that since the shareholding ratio of the company's non-public shareholders is as high as 74.9999%, in order to meet the requirement that the shareholding ratio of public shareholders as stipulated by the Beijing Stock Exchange is not less than 25%, according to estimates, the maximum number of shares the actual controller plans to increase its holdings this time can only be no more than 100 shares.
Although the plan to increase holdings is a “hopeless move” that has been restricted, the above explanation has failed to calm the dissatisfaction of the market and investors. Industry insiders believe that Haisheng Pharmaceutical's commitment arrangement in the prospectus can be said to be an embedded bug. There are obvious unreasonable and careless aspects, and there are not enough space reserved for specific implementation. As a result, the promise to stabilize stock prices was not actually implemented, but rather formalized.
In the latest announcement issued at midnight, Haisheng Pharmaceutical said that the company sincerely apologized to investors for not carefully formulating effective price stabilization measures in the early stages and for not fully considering the impact on the market and investors. The board of directors of the company will promptly study and formulate a practical price stabilization plan and release it as soon as possible after implementing the relevant decision-making procedures.
Haisheng Pharmaceutical further proposed that in the future, the company will continue to improve operational quality and efficiency, improve corporate governance, strengthen investor returns, use practical measures to convey the “investor-based” development concept to the market, fully protect the interests of small and medium-sized investors, and jointly promote the smooth operation of the market.
Analysts told the Financial Federation reporter that for Haisheng Pharmaceutical, this “most humble” holdings increase crisis has undoubtedly had a negative impact on the company's image and market confidence. However, it also provided an opportunity for the company to reflect and improve. Although Haisheng Pharmaceutical showed a positive attitude this time, the restoration of market confidence still needs to be supported by practical action. Therefore, Haisheng Pharmaceutical needs to pay more attention to communicating with investors, fully understanding market needs and expectations, and formulating more reasonable and effective measures to stabilize stock prices as soon as possible.